Literature DB >> 21106725

Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer.

Banibrata Sen1, Shaohua Peng, Babita Saigal, Michelle D Williams, Faye M Johnson.   

Abstract

PURPOSE: c-Src inhibition in cancer cells leads to an abrogation of invasion but a variable effect on apoptosis. The pathways downstream of c-Src promoting survival are not well characterized. Because cancer therapy that both decreases invasion and induces significant apoptosis would be ideal, we sought to characterize the mechanisms of resistance to c-Src inhibition. EXPERIMENTAL
DESIGN: c-Src was inhibited in a panel of oral cancer cell lines and subsequent survival and signaling measured. The interactions between c-Src and c-Met were evaluated using immunoprecitation and an in vitro kinase assay. Cytotoxicity was measured and the Chou-Talalay combination index calculated. An orthotopic model of oral cancer was used to assess the effects of c-Met and c-Src inhibitors.
RESULTS: Inhibition of c-Src resulted in c-Met inhibition in sensitive cells lines, but not in resistant cell lines. Isolated c-Met was a c-Src substrate in both sensitive and resistant cells, but there was no interaction of c-Src and c-Met in intact resistant cells. To examine the biological consequences of this mechanism, we demonstrated synergistic cytotoxicity, enhanced apoptosis, and decreased tumor size with the combination of c-Src and c-Met inhibitors.
CONCLUSIONS: Sustained c-Met activation can mediate resistance to c-Src inhibition. These data suggest that the differences between c-Met and c-Src signaling in sensitive and resistant cells are due to distinct factors promoting or inhibiting interactions, respectively, rather than to intrinsic structural changes in c-Src or c-Met. The synergistic cytotoxic effects of c-Src and c-Met inhibition may be important for the treatment of head and neck cancers. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106725      PMCID: PMC3460647          DOI: 10.1158/1078-0432.CCR-10-1617

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  Involvement of PI3-kinase and its association with c-Src in PTH-stimulated rat enterocytes.

Authors:  Claudia Gentili; Susana Morelli; Ana Russo De Boland
Journal:  J Cell Biochem       Date:  2002       Impact factor: 4.429

2.  Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance.

Authors:  D Uchida; H Kawamata; F Omotehara; T Kimura-Yanagawa; S Hino; N M Begum; M O Hoque; H Yoshida; M Sato; T Fujimori
Journal:  Int J Cancer       Date:  2001-08-15       Impact factor: 7.396

3.  Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.

Authors:  G Dong; Z Chen; Z Y Li; N T Yeh; C C Bancroft; C Van Waes
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

4.  Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B.

Authors:  Qinghua Zeng; Shaoqiong Chen; Zongbing You; Fan Yang; Thomas E Carey; Daniel Saims; Cun-Yu Wang
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

5.  Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells.

Authors:  M Jo; D B Stolz; J E Esplen; K Dorko; G K Michalopoulos; S C Strom
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

6.  Metalloproteinase expression in normal and malignant oral keratinocytes: stimulation of MMP-2 and -9 by scatter factor.

Authors:  J H Bennett; M J Morgan; S A Whawell; P Atkin; P Roblin; J Furness; P M Speight
Journal:  Eur J Oral Sci       Date:  2000-08       Impact factor: 2.612

7.  Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.

Authors:  J D Bergström; B Westermark; N E Heldin
Journal:  Exp Cell Res       Date:  2000-08-25       Impact factor: 3.905

8.  Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation.

Authors:  Tianyun Jiang; Yun Qiu
Journal:  J Biol Chem       Date:  2003-02-24       Impact factor: 5.157

9.  Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Authors:  Yiling Lu; Qinghua Yu; Jue Hui Liu; Jinyi Zhang; Hongwei Wang; Dimpy Koul; John S McMurray; Xianjun Fang; W K Alfred Yung; Kathy A Siminovitch; Gordon B Mills
Journal:  J Biol Chem       Date:  2003-07-17       Impact factor: 5.157

10.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.

Authors:  James G Christensen; Randall Schreck; Jon Burrows; Poonam Kuruganti; Emily Chan; Phuong Le; Jeffrey Chen; Xueyan Wang; Lany Ruslim; Robert Blake; Kenneth E Lipson; John Ramphal; Steven Do; Jingrong J Cui; Julie M Cherrington; Dirk B Mendel
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  30 in total

1.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

2.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

3.  Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.

Authors:  Pierre Saintigny; Shaohua Peng; Li Zhang; Banibrata Sen; Ignacio I Wistuba; Scott M Lippman; Luc Girard; John D Minna; John V Heymach; Faye M Johnson
Journal:  Mol Cancer Ther       Date:  2012-07-17       Impact factor: 6.261

Review 4.  The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.

Authors:  Andreas Varkaris; Paul G Corn; Sanchaika Gaur; Farshid Dayyani; Christopher J Logothetis; Gary E Gallick
Journal:  Expert Opin Investig Drugs       Date:  2011-10-28       Impact factor: 6.206

Review 5.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

6.  pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations.

Authors:  Gabriella Aquino; Giuseppe Pannone; Angela Santoro; Giuseppina Liguori; Renato Franco; Rosario Serpico; Gianluca Florio; Alfredo De Rosa; Marilena Mattoni; Valentina Cozza; Gerardo Botti; Simona Losito; Francesco Longo; Stefania Staibano; Giovanni Cuda; Lorenzo Lo Muzio; Carolina Sbordone; Pantaleo Bufo; Anna Grimaldi; Michele Caraglia; Marina Di Domenico
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

7.  Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.

Authors:  Lori Rice; Sharon Lepler; Christina Pampo; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2011-12-01       Impact factor: 5.150

Review 8.  RANK-mediated signaling network and cancer metastasis.

Authors:  Gina Chia-Yi Chu; Leland W K Chung
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

9.  Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation.

Authors:  Abdolkarim Moazeni-Roodi; Abdolamir Allameh; Iraj Harirchi; Maziar Motiee-Langroudi; Ata Garajei
Journal:  Pathol Oncol Res       Date:  2016-09-15       Impact factor: 3.201

10.  c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.

Authors:  Laura P Stabile; Guoqing He; Vivian Wai Yan Lui; Sufi Thomas; Cassandra Henry; Christopher T Gubish; Sonali Joyce; Kelly M Quesnelle; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.